RS52911B2 - Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda - Google Patents

Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda

Info

Publication number
RS52911B2
RS52911B2 RSP20130359A RS52911B2 RS 52911 B2 RS52911 B2 RS 52911B2 RS P20130359 A RSP20130359 A RS P20130359A RS 52911 B2 RS52911 B2 RS 52911B2
Authority
RS
Serbia
Prior art keywords
disease
parkinson
compound
treatment
daytime sleepiness
Prior art date
Application number
Other languages
English (en)
Serbian (sr)
Inventor
Jean-Charles Schwartz
Jeanne Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52911(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of RS52911B publication Critical patent/RS52911B/sr
Publication of RS52911B2 publication Critical patent/RS52911B2/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20130359 2005-04-01 2006-03-30 Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda RS52911B2 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06
PCT/IB2006/000739 WO2006103546A2 (en) 2005-04-01 2006-03-30 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands
EP06744466.1A EP1863487B2 (en) 2005-04-01 2006-03-30 Treatment of symptoms of parkinson's disease with non-imidazole alkylamines histamine h3-receptor ligands

Publications (2)

Publication Number Publication Date
RS52911B RS52911B (sr) 2014-02-28
RS52911B2 true RS52911B2 (sr) 2019-11-29

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20130359 RS52911B2 (sr) 2005-04-01 2006-03-30 Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda

Country Status (27)

Country Link
US (1) US8486947B2 (https=)
EP (2) EP1707203A1 (https=)
JP (3) JP5546761B2 (https=)
KR (1) KR101308527B1 (https=)
CN (1) CN101171009B (https=)
AU (1) AU2006228413C1 (https=)
BR (1) BRPI0612216B1 (https=)
CA (1) CA2603656C (https=)
CY (1) CY1114636T1 (https=)
DK (1) DK1863487T4 (https=)
EA (1) EA016007B1 (https=)
ES (1) ES2426008T5 (https=)
HR (1) HRP20130748T4 (https=)
MA (1) MA29353B1 (https=)
ME (1) ME01713B (https=)
MX (1) MX2007012162A (https=)
NO (1) NO343603B1 (https=)
NZ (1) NZ561940A (https=)
PL (1) PL1863487T5 (https=)
PT (1) PT1863487E (https=)
RS (1) RS52911B2 (https=)
SG (1) SG147415A1 (https=)
SI (1) SI1863487T2 (https=)
TN (1) TNSN07365A1 (https=)
UA (1) UA94902C2 (https=)
WO (1) WO2006103546A2 (https=)
ZA (1) ZA200708086B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HK1207004A1 (zh) * 2012-10-05 2016-01-22 Vtv治疗有限责任公司 治療輕度和中度阿爾茨海默病的方法
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11654283B2 (en) 2019-03-06 2023-05-23 Medtronic Xomed, Inc. Obstructive sleep apnea patient programmer for implantable devices
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
CN121175294A (zh) 2023-03-31 2025-12-19 生物计划制药公司 盐酸替洛利生的多晶型形式
WO2025082972A1 (en) * 2023-10-16 2025-04-24 Bioprojet Pharma Enteric coated pitolisant formulations and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JPH06505265A (ja) 1991-02-27 1994-06-16 シード・キャピタル・インベストメント・（エス・シー・アイ）・ベスローテン・フェンノートシャップ ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
DE69212164T2 (de) 1991-12-18 1996-12-05 Schering Corp., Kenilworth, N.J. Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
MX9207393A (es) 1991-12-18 1994-06-30 Schering Corp Imidazoil o alquilo de imidazoil susbtituido con una cadena heterociclica de cuatro o cinco miembros que contienen nitrogeno.
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
WO1994017058A1 (fr) 1993-01-25 1994-08-04 The Green Cross Corporation Compose d'imidazole
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
WO1995006037A1 (en) 1993-08-27 1995-03-02 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK0841922T3 (da) 1995-05-30 2002-06-03 Gliatech Inc 1H-4(5)-substituerede imidazolderivater
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
DK0841923T3 (da) 1995-06-07 2003-01-27 Gliatech Inc 1H-4(5)-substituerede imidazolderivater
RU2182904C2 (ru) 1996-02-09 2002-05-27 Джеймс Блэк Фаундейшн Лимитед Сульфонамиды и способы их получения
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
WO2000076957A1 (en) * 1999-06-11 2000-12-21 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
WO2002013821A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
EP1373218B9 (en) * 2001-03-29 2008-12-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Imidazolyl derivatives useful as histamine h3 receptor ligands
EP1451225A1 (en) * 2001-11-15 2004-09-01 Ortho-McNeil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
PT1451167E (pt) * 2001-12-10 2006-07-31 Ortho Mcneil Pharm Inc Fenilalcinos
US7279491B2 (en) * 2002-10-23 2007-10-09 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines
EP1642898B1 (en) * 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative

Also Published As

Publication number Publication date
CN101171009B (zh) 2012-11-07
SI1863487T2 (sl) 2019-11-29
CY1114636T1 (el) 2016-10-05
EP1707203A1 (en) 2006-10-04
PL1863487T5 (pl) 2021-08-09
US8486947B2 (en) 2013-07-16
KR101308527B1 (ko) 2013-09-17
SI1863487T1 (sl) 2013-09-30
MX2007012162A (es) 2007-11-22
CA2603656C (en) 2015-06-16
ES2426008T3 (es) 2013-10-18
MA29353B1 (fr) 2008-03-03
UA94902C2 (ru) 2011-06-25
DK1863487T4 (da) 2019-10-14
CN101171009A (zh) 2008-04-30
JP2014062126A (ja) 2014-04-10
DK1863487T3 (da) 2013-08-12
ME01713B (me) 2014-09-20
EP1863487B2 (en) 2019-07-17
BRPI0612216B1 (pt) 2022-04-19
US20090318433A1 (en) 2009-12-24
SG147415A1 (en) 2008-11-28
BRPI0612216A2 (pt) 2010-10-26
WO2006103546A2 (en) 2006-10-05
HRP20130748T4 (hr) 2019-11-15
PT1863487E (pt) 2013-08-29
NZ561940A (en) 2010-06-25
JP5955872B2 (ja) 2016-07-20
HRP20130748T1 (en) 2013-10-11
EA200702135A1 (ru) 2008-04-28
ES2426008T5 (es) 2020-03-20
AU2006228413C1 (en) 2012-02-02
RS52911B (sr) 2014-02-28
JP5546761B2 (ja) 2014-07-09
EP1863487A2 (en) 2007-12-12
AU2006228413B2 (en) 2011-09-15
PL1863487T3 (pl) 2014-10-31
WO2006103546A3 (en) 2007-03-01
AU2006228413A1 (en) 2006-10-05
EA016007B1 (ru) 2012-01-30
NO343603B1 (no) 2019-04-08
JP2016106142A (ja) 2016-06-16
CA2603656A1 (en) 2006-10-05
KR20080002904A (ko) 2008-01-04
JP2008534572A (ja) 2008-08-28
TNSN07365A1 (fr) 2008-12-31
NO20075086L (no) 2007-12-27
EP1863487B1 (en) 2013-05-29
ZA200708086B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
RS52911B2 (sr) Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda
AU2009257572C1 (en) Low dose topiramate/phentermine composition and methods of use thereof
JP2000507544A (ja) 痛みの治療方法
TW200808696A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
TWI453013B (zh) N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
EP1030667B1 (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
CA3046300C (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
TR2024013304A1 (tr) Modafi̇ni̇l ve sertrali̇n i̇çeren bi̇r tablet kombi̇nasyonu
TR2024013305A1 (tr) Modafi̇ni̇l ve fluokseti̇n i̇çeren kati formda bi̇r kombi̇nasyon
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
WO2010044108A2 (en) Controlled release formulations of ropinirole
HK40015061B (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
Rodnitzky et al. Anticholinergics
EA047115B1 (ru) Способы и композиции для лечения апноэ сна
AU2014202143A1 (en) Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
HK1029932B (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas